Literature DB >> 28550463

Histomorphometric changes following treatment for osteoporosis.

C A Moreira1, D W Dempster2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28550463     DOI： 10.1007/s40618-017-0662-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  7 in total

1.  Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

Authors:  Ian R Reid; Paul D Miller; Jacques P Brown; David L Kendler; Astrid Fahrleitner-Pammer; Ivo Valter; Katre Maasalu; Michael A Bolognese; Grattan Woodson; Henry Bone; Beiying Ding; Rachel B Wagman; Javier San Martin; Michael S Ominsky; David W Dempster
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

2.  Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.

Authors:  David W Dempster; Felicia Cosman; Hua Zhou; Jeri W Nieves; Mathias Bostrom; Robert Lindsay
Journal:  J Bone Miner Res       Date:  2016-03-21       Impact factor: 6.741

3.  Effect of Teriparatide on Bone Formation in the Human Femoral Neck.

Authors:  Felicia Cosman; David W Dempster; Jeri W Nieves; Hua Zhou; Marsha Zion; Catherine Roimisher; Yvonne Houle; Robert Lindsay; Mathias Bostrom
Journal:  J Clin Endocrinol Metab       Date:  2016-02-22       Impact factor: 5.958

Review 4.  Bone histomorphometry: a concise review for endocrinologists and clinicians.

Authors:  Carolina A Moreira Kulak; David W Dempster
Journal:  Arq Bras Endocrinol Metabol       Date:  2010-03

5.  Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.

Authors:  Pascale Chavassieux; Pierre J Meunier; Jean Paul Roux; Nathalie Portero-Muzy; Marlène Pierre; Roland Chapurlat
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

6.  Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

Authors:  Carolina A Moreira; Lorraine A Fitzpatrick; Yamei Wang; Robert R Recker
Journal:  Bone       Date:  2016-11-05       Impact factor: 4.398

7.  A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.

Authors:  David W Dempster; Hua Zhou; Robert R Recker; Jacques P Brown; Michael A Bolognese; Christopher P Recknor; David L Kendler; E Michael Lewiecki; David A Hanley; Sudhaker D Rao; Paul D Miller; Grattan C Woodson; Robert Lindsay; Neil Binkley; Jahangir Alam; Valerie A Ruff; Eileen R Gallagher; Kathleen A Taylor
Journal:  J Bone Miner Res       Date:  2016-03-08       Impact factor: 6.741
  7 in total
  3 in total

Review 1.  New anabolic therapies for osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Marco Occhiuto; Jessica Pepe
Journal:  Intern Emerg Med       Date:  2017-08-05       Impact factor: 3.397

Review 2.  State of the art in osteoporosis risk assessment and treatment.

Authors:  J Liu; E M Curtis; C Cooper; N C Harvey
Journal:  J Endocrinol Invest       Date:  2019-04-12       Impact factor: 4.256

Review 3.  Update on the safety and efficacy of teriparatide in the treatment of osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Giada Della Grotta; Luciano Colangelo; Marco Occhiuto; Piergianni Biondi; Chiara Sonato; Evelina Vigna; Mirella Cilli; Jessica Pepe
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-10-05       Impact factor: 5.346
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.